A2 Biotherapeutics, headquartered in Agoura Hills, California, announced receipt of US FDA Fast Track Designation for A2B543, an autologous logic-gated chimeric antigen receptor (CAR) T-cell therapy, for the treatment of germline heterozygous HLA-A02 adults with recurrent unresectable, locally advanced, or metastatic solid tumors expressing mesothelin (MSLN) that have lost HLA-A02 expression. The Fast Track status is the first such regulatory status awarded to the program.
Fast Track designation enables rolling review of application sections and more frequent FDA interactions, and may facilitate eligibility for Priority Review or Accelerated Approval if relevant criteria are met.
A2B543 is constructed from autologous Tmod cells encoding three functional components: a MSLN-targeted CAR activator, an HLA-A02-targeted blocker, and an inducible membrane-tethered interleukin-12 (mem-IL-12) booster. The activator drives cytotoxic engagement with MSLN-expressing tumor cells, while the blocker suppresses T-cell activation in the presence of HLA-A02 on normal tissue — a logic-gating architecture designed to restrict killing to cells that have undergone allelic loss of HLA-A02, a somatic event observed across multiple solid tumor histologies. The mem-IL-12 booster is engineered to activate only upon tumor antigen engagement, with the stated aim of enhancing T-cell persistence and potency while avoiding the systemic toxicity associated with soluble IL-12. Preclinical support for this approach was published in the Journal for ImmunoTherapy of Cancer in 2025 by Zhang et al.
A2B543 is currently under evaluation as Arm 2 of the Phase I/II EVEREST-2 study (NCT06051695), which also enrolls patients to Arm 1 receiving A2B694, a related Tmod construct without the mem-IL-12 component. EVEREST-2 enrolls patients with colorectal, pancreatic, non-small cell lung, ovarian, and mesothelioma histologies, alongside other MSLN-expressing solid tumors with confirmed HLA-A*02 loss. A2B543 dosed its first patient in February 2026.
Research context
CAR T-cell therapy has achieved regulatory approval in hematologic malignancies but has not yet produced an approved product for solid tumors, where dense stroma, antigen heterogeneity, and an immunosuppressive microenvironment have limited efficacy. MSLN is expressed across several high-mortality tumor types including pancreatic adenocarcinoma, malignant pleural mesothelioma, and ovarian carcinoma, making it a recurring target in solid tumor cell therapy programs. However, MSLN is also present on normal mesothelial cells, creating an on-target, off-tumor toxicity risk that has constrained prior approaches.
The logic-gating strategy employed by A2B543 attempts to resolve this selectivity problem by requiring simultaneous MSLN expression and HLA-A02 loss for T-cell activation — a condition that, in theory, restricts cytotoxic activity to tumor cells that have undergone loss of heterozygosity at the HLA locus. Unlike conventional MSLN-directed CAR T constructs, which rely on a single activating receptor, A2B543 uses the Tmod dual-receptor design to introduce a conditional inhibitory signal in normal tissue. A related compound in EVEREST-2, A2B694, lacks the mem-IL-12 booster; data from Arm 1 presented at the Society for Immunotherapy of Cancer annual meeting in October 2025 reported no dose-limiting toxicities, no cytokine release syndrome across treated patients, and one complete response in a patient with NSCLC after 8.9 months of follow-up — the first reported complete response to any CAR T-cell therapy in that histology. Those results were generated from A2B694 and do not directly establish the clinical profile of A2B543, though the shared platform architecture provides mechanistic context.
The competitive landscape for MSLN-targeted solid tumor therapy remains early-stage. No MSLN-directed cell therapy has received FDA approval. Multiple programs in clinical development target MSLN through CAR T, T-cell receptor (TCR), or antibody-drug conjugate (ADC) formats, but none has advanced to a registrational trial on the basis of efficacy in an unselected solid tumor population. The HLA-loss gating strategy distinguishes A2B543 from single-receptor MSLN CAR T approaches by adding a tumor-selectivity mechanism, though the clinical consequences of that design difference remain to be established in patients.